Prognostic value of renal hemodynamic characteristics in patients with proliferative lupus nephritis

Kidney and Blood Pressure Research

Volumn 30, Issue 3, 2007, Pages 175-181

  Martens, Henk A ^a   Bijl, Marc ^a   Kallenberg, Cees G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Lupus nephritis; Prognosis, lupus nephritis; Proliferative lupus nephritis; Renal hemodynamics, lupus nephritis; Systemic lupus erythematosus

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ADOLESCENT; ADULT; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; FEMALE; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY BLOOD FLOW; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; RETROSPECTIVE STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT FAILURE;

ADOLESCENT; ADULT; CREATININE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; RENAL CIRCULATION; RETROSPECTIVE STUDIES;

EID: 34250899084     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000102986     Document Type: Article

References (18)

1. Wallace DJ, Hahn BH (eds): Dubois' Lupus Erythematosus, ed 6. Philadelphia, Lippincott/Williams & Wilkins, 2002.
2. Baldwin DS, Lowenstein J, Rothfield NF, Gallo G, McCluskey RT: The clinical course of the proliferative and membranous forms of lupus nephritis. Ann Intern Med 1970;73:929-942.
3. Felson DT, Anderson J: Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med 1984;311:1528-1533.
4. Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, Decker JL: Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-619.
5. Mok CC: Prognostic factors in lupus nephritis. Lupus 2005;14:39-44.
6. Derksen RH, Hene RJ, Kater L: The longterm clinical outcome of 56 patients with biopsy-proven lupus nephritis followed at a single center. Lupus 1992;1:97-103.
7. Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohde RD: Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 2000;35:904-914.
8. Nakano M, Ueno M, Hasegawa H, Watanabe T, Kuroda T, Ito S, Arakawa M: Renal haemodynamic characteristics in patients with lupus nephritis. Ann Rheum Dis 1998;57:226-230.
9. Kallenberg CG, Schweitzer C, de Jong PE, Donker AJ, van der Hem GK: Decreased filtration fraction during active proliferative lupus nephritis: relation to disease activity and reversibility of renal function. Clin Nephrol 1984;22:223-229.
10. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M: The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241-250.
11. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-1277.
12. Donker AJ, van der Hem GK, Sluiter WJ, Beekhuis H: A radioisotope method for simultaneous determination of the glomerular filtration rate and the effective renal plasma flow. Neth J Med 1977;20:97-103.
13. Shemesh O, Golbetz H, Kriss JP, Myers BD: Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985;28:830-838.
14. Chagnac A, Kiberd BA, Farinas MC, Strober S, Sibley RK, Hoppe R, Myers BD: Outcome of the acute glomerular injury in proliferative lupus nephritis. J Clin Invest 1989;84:922-930.
15. 2 production in patients with systemic lupus erythematosus. J Clin Invest 1985;76:1011-1018.
16. 2 synthetase inhibitor, DP-1904. Lupus 1996;5:129-138.
17. El Hachmi M, Jadoul M, Lefebvre C, Depresseux G, Houssiau FA: Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome. Lupus 2003;12:692-696.
18. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gul A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R: Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from longterm follow-up of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004;50:3934-3940.